Clinical Trials Logo

Synchronous Neoplasms clinical trials

View clinical trials related to Synchronous Neoplasms.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02805530 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma

Start date: June 2015
Phase: N/A
Study type: Interventional

Non-small cell lung cancer (NSCLC) is the most frequent neoplasm worldwide and also represents the main cause of cancer death. However, it represents the main cause of death by cancer. The prognosis of survival at 5 years is poor, approximately 13-15%. Various studies suggest that patients who clinically present with a limited number of metastases, a term defined as oligometastatic disease, could have a better prognosis of survival with a radical treatment, than for their counterparts with a greater number of metastasis. The purpose of this study is to add more information to the current medical literature about the benefits in overall survival of radical treatment of oligometastatic disease in patients with NSCLC and equal or less than 5 synchronous metastases at the time of diagnosis. The outcomes of the study are to determine the global survival and progression-free survival in patients with synchronous oligometastatic (equal to or less than 5 sites) advanced NSCLC undergoing radical treatment of all metastatic sites and the primary tumor.